Temporal Profiling of Molecular Alterations in the Hypothalamic Paraventricular Nucleus During Angiotensin‐II Hypertension

Abstract

The hypothalamic paraventricular nucleus (PVN) plays a central role in cardiovascular regulation including hypertension development in response to elevations in angiotensin-II (Ang-II). Upstream circumventricular nuclei located outside of the blood-brain-barrier sense circulating Ang-II and influence PVN endocrine and autonomic regulation via efferent synaptic projections. Despite progress in unraveling the function of circumventricular-PVN networks in neurogenic hypertension development, the underlying PVN mechanisms responsible for hypertension development remain unclear. In particular, most investigations have examined PVN alterations during established hypertension, which limits insight into molecular changes that may occur prior to hypertension development. Based on this, we performed a detailed temporal profiling of key molecular targets in the PVN during Ang-II hypertension progression. Male C57Bl/6J mice were implanted with subcutaneous osmotic minipumps for chronic delivery of low dose Ang-II (600 ng/kg/min). Brains were harvested for immunohistochemistry analysis of target molecules across rostral to caudal subregions of the PVN (n=3-4/group) at baseline (day 0), pre-hypertensive (days 3 and 7), and established-hypertension (day 14) timepoints. Previous work has suggested a role for arginine vasopressin (AVP) in Ang-II-induced hypertension. In line with this, AVP immunoreactivity in the PVN was elevated within 3 days of Ang-II infusion; this was evident only in the caudal PVN (day 3 fold change: 2.5±0.2, density/cell, p<0.05), whereas AVP expression in the rostral and medial portions was unchanged. Interestingly, caudal AVP immunoreactivity returned to basal levels by day 7 and remained low for the remainder of the protocol. In contrast to AVP, oxytocin expression was unchanged across the rostral to caudal PVN during 2-week Ang-II hypertension development. We also measured preproenkephalin (PPE) immunoreactivity, and found a progressive increase throughout the entire PVN with elevations initiated at pre-hypertensive times (day 7 fold change: 2.0±0.1, density/area, p=0.08) that were sustained during established hypertension (day 14 fold change: 2.6±0.3, density/area, p<0.05). To test possible involvement of the arcuate nucleus, which transmits circulating information from the median eminence to the PVN, in Ang-II hypertension, we measured alpha-melanocortin stimulating hormone (alpha-MSH) levels. Histological analysis for alpha-MSH immunoreactivity in the PVN, as an indicator of synaptic innervation strength from arcuate nucleus proopiomelanocortin neurons, revealed no changes during Ang-II infusion. Collectively, these findings indicate elevations in PVN AVP and PPE, but not oxytocin and alpha-MSH, in response to elevations in circulating Ang-II. Furthermore, the temporal responses suggest that different PVN molecules may be responsible for the initiation (e.g. AVP) versus maintenance (e.g. PPE) of Ang-II hypertension.